{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:27:11Z","timestamp":1790958431902,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Gene therapy is an emerging topic in medicine. The first products have already been licensed in the European Union for the treatment of immune deficiency, spinal muscular atrophy, hemophilia, retinal dystrophy, a\u00a0rare neurotransmitter disorder and some hematological cancers, while many more are being assessed in preclinical and clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The purpose of this review is to provide an overview of the core principles of gene therapy along with information on challenges and risks. Benefits, adverse effects and potential risks are illustrated based on the examples of hemophilia and spinal muscular atrophy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At present, <jats:italic>in-vitro<\/jats:italic> and <jats:italic>in-vivo<\/jats:italic> gene addition or gene augmentation is the most commonly established type of gene therapy. More recently, more sophisticated and precise approaches such as <jats:italic>in situ<\/jats:italic> gene editing have moved into focus. However, all types of gene therapy require long-term observation of treated patients to ensure safety, efficacy, predictability and durability. Important safety concerns include immune reactions to the vector, the foreign DNA or the new protein resulting from gene therapy, and a\u00a0remaining low cancer risk based on insertional mutagenesis. Ethical and regulatory issues need to be addressed, and new reimbursement models are called for to ease the financial burden that this new treatment poses for the health care system.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Gene therapy holds great promise for considerable improvement or even cure of genetic diseases with serious clinical consequences. However, a\u00a0number of questions and issues need to be clarified to ensure broad accessibility of safe and efficacious products.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00508-024-02368-8","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T05:01:49Z","timestamp":1715058109000},"page":"261-271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Gene therapy: principles, challenges and use in clinical practice"],"prefix":"10.1007","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"4025","key":"2368_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.175.4025.949","volume":"175","author":"T Friedmann","year":"1972","unstructured":"Friedmann\u00a0T, Roblin\u00a0R. Gene therapy for human genetic disease? Science. 1972;175(4025):949\u201355. https:\/\/doi.org\/10.1126\/science.175.4025.949.","journal-title":"Science"},{"key":"2368_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela\u00a0XM, High\u00a0KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273\u201388. https:\/\/doi.org\/10.1146\/annurev-med-012017-043332.","journal-title":"Annu Rev Med"},{"issue":"6753","key":"2368_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/43977","volume":"401","author":"S Lehrman","year":"1999","unstructured":"Lehrman\u00a0S. Virus treatment questioned after gene therapy death. Nature. 1999;401(6753):517\u20138. https:\/\/doi.org\/10.1038\/43977.","journal-title":"Nature"},{"key":"2368_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80(1\u20132","author":"SE Raper","year":"2003","unstructured":"Raper\u00a0SE, Chirmule\u00a0N, Lee\u00a0FS, Wivel\u00a0NA, Bagg\u00a0A, Gao\u00a0GP, et\u00a0al. Fatal systemic inflammatory response syndrome in a\u00a0ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1\u20132:148\u201358.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"2368_CR5","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"S Hacein-Bey-Abina","year":"2008","unstructured":"Hacein-Bey-Abina\u00a0S, Garrigue\u00a0A, Wang\u00a0GP, Soulier\u00a0J, Lim\u00a0A, Morillon\u00a0E, et\u00a0al. Insertional oncogenesis in 4\u00a0patients after retrovirus-mediated gene therapy of SCID-X1. J\u00a0Clin Invest. 2008;118(9):3132\u201342. https:\/\/doi.org\/10.1172\/JCI35700.","journal-title":"J Clin Invest"},{"issue":"5644","key":"2368_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina\u00a0S, Von Kalle\u00a0C, Schmidt\u00a0M, McCormack\u00a0MP, Wulffraat\u00a0N, Leboulch\u00a0P, et\u00a0al. LMO2-associated clonal T\u00a0cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415\u20139. https:\/\/doi.org\/10.1126\/science.1088547.","journal-title":"Science"},{"issue":"3","key":"2368_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina\u00a0S, Von Kalle\u00a0C, Schmidt\u00a0M, Le Deist\u00a0F, Wulffraat\u00a0N, McIntyre\u00a0E, et\u00a0al. A\u00a0serious adverse event after successful gene therapy for X\u2011linked severe combined immunodeficiency. N\u00a0Engl J Med. 2003;348(3):255\u20136. https:\/\/doi.org\/10.1056\/NEJM200301163480314.","journal-title":"N Engl J Med"},{"issue":"11","key":"2368_CR8","first-page":"1612","volume":"164","author":"B Sibbald","year":"2001","unstructured":"Sibbald\u00a0B. Death but one unintended consequence of gene-therapy trial. Cmaj. 2001;164(11):1612.","journal-title":"Cmaj"},{"key":"2368_CR9","unstructured":"American Society of Gene. Cell Therapy. Gene, cell, + RNA Therapy Landscape Report Q3. Quarterly. 2023;. Data Report."},{"key":"2368_CR10","doi-asserted-by":"crossref","unstructured":"Rupp VM, Windisch M. Healthcare professionals in Austria are positive about gene therapy, but expressed a\u00a0need for more topic related education. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research, 21\u201324th February 2023, Frankfurt, Germany. Poster T\u201116-04.","DOI":"10.1055\/s-0042-1760569"},{"issue":"5","key":"2368_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","volume":"381","author":"KA High","year":"2019","unstructured":"High\u00a0KA, Therapy\u00a0RMGG. N\u00a0Engl J Med. 2019;381(5):455\u201364. https:\/\/doi.org\/10.1056\/NEJMra1706910.","journal-title":"N Engl J Med"},{"issue":"10","key":"2368_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMra1800729","volume":"380","author":"MH Porteus","year":"2019","unstructured":"Porteus\u00a0MH. A\u00a0new class of medicines through DNA editing. N\u00a0Engl J Med. 2019;380(10):947\u201359. https:\/\/doi.org\/10.1056\/NEJMra1800729.","journal-title":"N Engl J Med"},{"key":"2368_CR13","unstructured":"Summary of Product Characteristics Casgevy\u00ae"},{"key":"2368_CR14","doi-asserted-by":"publisher","unstructured":"Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 211;12(5):301\u201315. https:\/\/doi.org\/10.1038\/nrg2985.","DOI":"10.1038\/nrg2985"},{"issue":"5","key":"2368_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi\u00a0F, High\u00a0KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12(5):341\u201355. https:\/\/doi.org\/10.1038\/nrg2988.","journal-title":"Nat Rev Genet"},{"issue":"6372","key":"2368_CR16","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar\u00a0CE, High\u00a0KA, Joung\u00a0JK, Kohn\u00a0DB, Ozawa\u00a0K, Sadelain\u00a0M. Gene therapy comes of age. Science. 2018;359(6372):eaan4672. https:\/\/doi.org\/10.1126\/science.aan4672.","journal-title":"Science"},{"issue":"97","key":"2368_CR17","first-page":"67","volume":"18","author":"D Wang","year":"2014","unstructured":"Wang\u00a0D, Gau\u00a0G. State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med. 2014;18(97):67\u201377.","journal-title":"Discov Med"},{"issue":"11","key":"2368_CR18","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1002\/emmm.201202287","volume":"5","author":"KB Kaufmann","year":"2013","unstructured":"Kaufmann\u00a0KB, B\u00fcning\u00a0H, Galy\u00a0A, Schambach\u00a0A, Grez\u00a0M. Gene therapy on the move. EMBO Mol Med. 2013;5(11):1642\u201361. https:\/\/doi.org\/10.1002\/emmm.201202287.","journal-title":"EMBO Mol Med"},{"key":"2368_CR19","doi-asserted-by":"crossref","unstructured":"Nathwani AC, Reiss U, Tuddenham E, Chowdary P, McIntosh J, Riddell A, et\u00a0al. Adeno-associated mediated gene transfer for hemophilia B: 8\u00a0year follow up and impact of removing \u201cempty viral particles\u201d on safety and efficacy of gene transfer. Blood. 2018;132(Supplement 1):491.","DOI":"10.1182\/blood-2018-99-118334"},{"issue":"6","key":"2368_CR20","first-page":"357","volume":"2","author":"TR Flotte","year":"1995","unstructured":"Flotte\u00a0TR, Carter\u00a0BJ. Adeno-associated virus vectors for gene therapy. Gene Ther. 1995;2(6):357\u201362.","journal-title":"Gene Ther"},{"issue":"4","key":"2368_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri\u00a0M, Levy\u00a0DI, Schulz\u00a0M, McCarty\u00a0D, Gao\u00a0G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30(4):1364\u201380. https:\/\/doi.org\/10.1016\/j.ymthe.2022.03.004.","journal-title":"Mol Ther"},{"issue":"5","key":"2368_CR22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang\u00a0D, Tai\u00a0PWL, Gao\u00a0G. Adeno-associated virus vector as a\u00a0platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2368_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"HC Verdera","year":"2020","unstructured":"Verdera\u00a0HC, Kuranda\u00a0K, Mingozzi\u00a0F. AAV Vector Immunogenicity in Humans: A\u00a0Long Journey to Successful Gene Transfer. Mol Ther. 2020;28(3):723\u201346. https:\/\/doi.org\/10.1016\/j.ymthe.2019.12.010.","journal-title":"Mol Ther"},{"issue":"1","key":"2368_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha\u00a0JT, Wang\u00a0Y, Ma\u00a0H, Tai\u00a0PWL, Gao\u00a0G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. https:\/\/doi.org\/10.1038\/s41392-021-00487-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"85","key":"2368_CR25","first-page":"379","volume":"15","author":"E Masat","year":"2013","unstructured":"Masat\u00a0E, Pavani\u00a0G, Mingozzi\u00a0F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med. 2013;15(85):379\u201389.","journal-title":"Discov Med"},{"issue":"4","key":"2368_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso\u00a0MF, Tomkowicz\u00a0B, Perry\u00a0WL 3rd, Strohl\u00a0WR. Adeno-Associated virus (AAV) as a\u00a0vector for gene therapy. BioDrugs. 2017;31(4):317\u201334. https:\/\/doi.org\/10.1007\/s40259-017-0234-5.","journal-title":"BioDrugs"},{"issue":"5","key":"2368_CR27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cells12050785","volume":"12","author":"SS Issa","year":"2023","unstructured":"Issa\u00a0SS, Shaimardanova\u00a0AA, Solovyeva\u00a0VV, Rizvanov\u00a0AA. Various AAV serotypes and their applications in gene therapy: an overview. Cells. 2023;12(5):785. https:\/\/doi.org\/10.3390\/cells12050785.","journal-title":"Cells"},{"issue":"3","key":"2368_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/v15030698","volume":"15","author":"K Lundstrom","year":"2023","unstructured":"Lundstrom\u00a0K. Viral vectors in gene therapy: Where do we stand in 2023? Viruses. 2023;15(3):698. https:\/\/doi.org\/10.3390\/v15030698.","journal-title":"Viruses"},{"issue":"12","key":"2368_CR29","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1182\/blood-2010-08-302729","volume":"117","author":"H Li","year":"2011","unstructured":"Li\u00a0H, Malani\u00a0N, Hamilton\u00a0SR, Schlachterman\u00a0A, Bussadori\u00a0G, Edmonson\u00a0SE, et\u00a0al. Assessing the potential for AAV vector genotoxicity in a\u00a0murine model. Blood. 2011;117(12):3311\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-302729.","journal-title":"Blood"},{"key":"2368_CR30","doi-asserted-by":"publisher","unstructured":"Wellman JA, Mingozzi F, Ozelo MC, Arruda V, Podsakoff G, Chen Y, et\u00a0al. Results from long-term follow-up of severe hemophilia B subjects previously enrolled in a\u00a0clinical study of AAV2-FIX gene transfer to the liver. Mol Ther. 2012;20:S28\u20139. https:\/\/doi.org\/10.1016\/S1525-0016(16)35873-7.","DOI":"10.1016\/S1525-0016(16)35873-7"},{"issue":"8","key":"2368_CR31","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/hae.13810","volume":"64","author":"M Weiller","year":"2019","unstructured":"Weiller\u00a0M, Coulibaly\u00a0S, Gritsch\u00a0H, Wang\u00a0H, Rottensteiner\u00a0H, Chuah\u00a0MK, et\u00a0al. Nonclinical safety evaluation of a\u00a0next generation factor\u00a0IX (FIX) gene therapy construct (SHP. Mice Haemophilia. 2019;64(8):138. https:\/\/doi.org\/10.1111\/hae.13810.","journal-title":"Mice Haemophilia"},{"issue":"6148","key":"2368_CR32","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi\u00a0A, Montini\u00a0E, Lorioli\u00a0L, Cesani\u00a0M, Fumagalli\u00a0F, Plati\u00a0T, et\u00a0al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science. 2013;341(6148):1233158. https:\/\/doi.org\/10.1126\/science.1233158.","journal-title":"Science"},{"issue":"16","key":"2368_CR33","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson\u00a0AA, Walters\u00a0MC, Kwiatkowski\u00a0J, Rasko\u00a0JEJ, Ribeil\u00a0JA, Hongeng\u00a0S, et\u00a0al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N\u00a0Engl J Med. 2018;378(16):1479\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1705342.","journal-title":"N Engl J Med"},{"key":"2368_CR34","unstructured":"Summary of Product Characteristics Roctavian\u00ae."},{"key":"2368_CR35","unstructured":"Summary of Product Characteristics Hemgenix\u00ae."},{"issue":"9","key":"2368_CR36","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"SJ Howe","year":"2008","unstructured":"Howe\u00a0SJ, Mansour\u00a0MR, Schwarzwaelder\u00a0K, Bartholomae\u00a0C, Hubank\u00a0M, Kempski\u00a0H, et\u00a0al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J\u00a0Clin Invest. 2008;118(9):3143\u201350. https:\/\/doi.org\/10.1172\/JCI35798.","journal-title":"J Clin Invest"},{"key":"2368_CR37","doi-asserted-by":"publisher","unstructured":"Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, et\u00a0al. Gene therapy for Wiskott-Aldrich syndrome\u2014long-term efficacy and genotoxicity. Sci Transl Med. 2014;6(227):227ra33. https:\/\/doi.org\/10.1126\/scitranslmed.3007280.","DOI":"10.1126\/scitranslmed.3007280"},{"issue":"4","key":"2368_CR38","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm1393","volume":"12","author":"MG Ott","year":"2006","unstructured":"Ott\u00a0MG, Schmidt\u00a0M, Schwarzwaelder\u00a0K, Stein\u00a0S, Siler\u00a0U, Koehl\u00a0U, et\u00a0al. Correction of X\u2011linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401\u20139. https:\/\/doi.org\/10.1038\/nm1393.","journal-title":"Nat Med"},{"issue":"8","key":"2368_CR39","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nri859","volume":"2","author":"A Fischer","year":"2002","unstructured":"Fischer\u00a0A, Hacein-Bey\u00a0S, Cavazzana-Calvo\u00a0M. Gene therapy of severe combined immunodeficiencies. Nat Rev Immuno. 2002;2(8):615\u201321. https:\/\/doi.org\/10.1038\/nri859.","journal-title":"Nat Rev Immuno"},{"key":"2368_CR40","doi-asserted-by":"publisher","unstructured":"Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond; HE, Leiby J, et\u00a0al. A\u00a0long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47\u201355. https:\/\/doi.org\/10.1038\/s41587-020-0741-7.","DOI":"10.1038\/s41587-020-0741-7"},{"issue":"2","key":"2368_CR41","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1172\/JCI79213","volume":"125","author":"RJ Chandler","year":"2015","unstructured":"Chandler\u00a0RJ, FaFave\u00a0MC, Varshney\u00a0GK, Trivedi\u00a0NS, Carrillo-Carrasco\u00a0N, Senac\u00a0JS, et\u00a0al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. Clin Invest. 2015;125(2):870\u201380. https:\/\/doi.org\/10.1172\/JCI79213.","journal-title":"Clin Invest"},{"issue":"4","key":"2368_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/hum.2017.009","volume":"28","author":"RJ Chandler","year":"2017","unstructured":"Chandler\u00a0RJ, Sands\u00a0MS, Venditti\u00a0CP. Recombinant adeno-associated virus integration and genotoxicity: Insights from animal models. Hum Gene Ther. 2017;28(4):314\u201322. https:\/\/doi.org\/10.1089\/hum.2017.009.","journal-title":"Hum Gene Ther"},{"issue":"5837","key":"2368_CR43","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1126\/science.1142658","volume":"317","author":"A Donsante","year":"2007","unstructured":"Donsante\u00a0A, Miller\u00a0DG, Li\u00a0Y, Vogler\u00a0C, Brunt\u00a0EM, Russell\u00a0DW, Sands\u00a0MS. AAV vector integration sites in mouse hepatocellular carcinoma. Science. 2007;317(5837):477. https:\/\/doi.org\/10.1126\/science.1142658.","journal-title":"Science"},{"issue":"25","key":"2368_CR44","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani\u00a0AC, Tuddenham\u00a0EGD, Rangarajan\u00a0S, Rosales\u00a0C, McIntosh\u00a0J, Linch\u00a0DC, et\u00a0al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N\u00a0Engl J Med. 2011;365(25):2357\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1108046.","journal-title":"N Engl J Med"},{"issue":"4","key":"2368_CR45","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/brv.12718","volume":"96","author":"M Whitehead","year":"2021","unstructured":"Whitehead\u00a0M, Osborne\u00a0A, Yu-Wai-Man\u00a0P, Martin\u00a0K. Humoral immune responses to AAV gene therapy in the ocular compartment. Biol Rev Camb Philos Soc. 2021;96(4):1616\u201344. https:\/\/doi.org\/10.1111\/brv.12718.","journal-title":"Biol Rev Camb Philos Soc"},{"key":"2368_CR46","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","volume":"10","author":"M Zheng","year":"2019","unstructured":"Zheng\u00a0M, Tian\u00a0Z. Liver-mediated adaptive immune tolerance. Front Immunol. 2019;10:2525. https:\/\/doi.org\/10.3389\/fimmu.2019.02525.","journal-title":"Front Immunol"},{"key":"2368_CR47","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","volume":"23","author":"DH Chand","year":"2021","unstructured":"Chand\u00a0DH, Zaidman\u00a0C, Arya\u00a0K, Millner\u00a0R, Farrar\u00a0MA, Mackie\u00a0FE, et\u00a0al. Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: A\u00a0case series. J\u00a0Pediatr. 2021;23:265\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2020.11.054.","journal-title":"J Pediatr"},{"key":"2368_CR48","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl\u00a0HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803. https:\/\/doi.org\/10.3389\/fimmu.2022.975803.","journal-title":"Front Immunol"},{"key":"2368_CR49","unstructured":"Summary of Product Characteristics Kymriah\u00ae."},{"key":"2368_CR50","unstructured":"Summary of Product Characteristics Yescarta\u00ae."},{"key":"2368_CR51","unstructured":"Summary of Product Characteristics Tecartus\u00ae."},{"key":"2368_CR52","unstructured":"Summary of Product Characteristics Breyanzi\u00ae."},{"key":"2368_CR53","unstructured":"Summary of Product Characteristics Abecma\u00ae."},{"key":"2368_CR54","unstructured":"Summary of Product Characteristics Carvykti\u00ae."},{"key":"2368_CR55","unstructured":"Summary of Product Characteristics Imlygic\u00ae."},{"key":"2368_CR56","unstructured":"Summary of Product Characteristics Strimvelis\u00ae."},{"key":"2368_CR57","unstructured":"Summary of Product Characteristics Luxturna\u00ae."},{"key":"2368_CR58","unstructured":"Summary of Product Characteristics Upstaza\u00ae ."},{"key":"2368_CR59","unstructured":"Summary of Product Characteristics Libmeldy\u00ae."},{"key":"2368_CR60","unstructured":"Summary of Product Characteristics Zolgensma\u00ae."},{"issue":"1","key":"2368_CR61","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava\u00a0A, Brewer\u00a0AK, Mauser-Bunschoten\u00a0EP, Key\u00a0NS, Kitchen\u00a0S, Llinas\u00a0A, et\u00a0al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1\u201347. https:\/\/doi.org\/10.1111\/j.1365-2516.","journal-title":"Haemophilia"},{"issue":"1","key":"2368_CR62","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","volume":"7","author":"E Berntorp","year":"2021","unstructured":"Berntorp\u00a0E, Fischer\u00a0K, Hart\u00a0DP, Mancuso\u00a0ME, Stephensen\u00a0D, Shapiro\u00a0AM, Hemophilia\u00a0BV. Nat Rev Dis Primers. 2021;7(1):45. https:\/\/doi.org\/10.1038\/s41572-021-00278-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2368_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","volume":"133","author":"GQ Perrin","year":"2019","unstructured":"Perrin\u00a0GQ, Herzog\u00a0RW, Markusic\u00a0DM. Update on clinical gene therapy for hemophilia. Blood. 2019;133(5):407\u201314. https:\/\/doi.org\/10.1182\/blood-2018-07-820720.","journal-title":"Blood"},{"issue":"6","key":"2368_CR64","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli\u00a0C, Soltys\u00a0S, Rengo\u00a0G, Rabinowitz\u00a0JE. Analysis of AAV serotypes 1\u20139 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16(6):1073\u201380. https:\/\/doi.org\/10.1038\/mt.2008.76.","journal-title":"Mol Ther"},{"issue":"9","key":"2368_CR65","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3324\/haematol.2019.221093","volume":"104","author":"G Castaman","year":"2019","unstructured":"Castaman\u00a0G, Matino\u00a0D. Hemophilia A and\u00a0B:\u00a0molecular and clinical similarities and differences. Haematologica. 2019;104(9):1702\u20139. https:\/\/doi.org\/10.3324\/haematol.2019.221093.","journal-title":"Haematologica"},{"issue":"3","key":"2368_CR66","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1097\/HS9.0000000000000540","volume":"5","author":"P Batty","year":"2021","unstructured":"Batty\u00a0P, Lillicrap\u00a0D. Hemophilia gene therapy: approaching the first licensed product. HemaSphere. 2021;5(3):e540. https:\/\/doi.org\/10.1097\/HS9.0000000000000540.","journal-title":"HemaSphere"},{"key":"2368_CR67","doi-asserted-by":"publisher","unstructured":"Srivastava A, Santagostino E , Dougall A, Kitchen S, Sutherland M, Pipe SW, et\u00a0al. WFH guidelines for the management of haemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","DOI":"10.1111\/hae.14046"},{"issue":"21","key":"2368_CR68","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood-2017-08-742312","volume":"130","author":"VR Arruda","year":"2017","unstructured":"Arruda\u00a0VR, Doshi\u00a0BS, Samelson-Jones\u00a0BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130(21):2251\u20136. https:\/\/doi.org\/10.1182\/blood-2017-08-742312.","journal-title":"Blood"},{"issue":"R1","key":"2368_CR69","doi-asserted-by":"publisher","first-page":"R36","DOI":"10.1093\/hmg\/ddv475","volume":"25","author":"KA High","year":"2016","unstructured":"High\u00a0KA, Anguela\u00a0XM. Adeno-associated viral vectors for the treatment of hemophilia. Hum Mol Genet. 2016;25(R1):R36\u201341. https:\/\/doi.org\/10.1093\/hmg\/ddv475.","journal-title":"Hum Mol Genet"},{"key":"2368_CR70","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","volume":"361","author":"P Simioni","year":"2009","unstructured":"Simioni\u00a0P, Tormene\u00a0D, Tognin\u00a0G, et\u00a0al. X\u2011linked thrombophilia with a\u00a0mutant factor\u00a0IX (factor\u00a0IX Padua). N\u00a0Engl J Med. 2009;361:1671\u20135.","journal-title":"N Engl J Med"},{"issue":"26","key":"2368_CR71","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan\u00a0S, Walsh\u00a0L, Lester\u00a0W, Perry\u00a0D, Madan\u00a0B, Laffan\u00a0M, et\u00a0al. AAV5-factor\u00a0VIII gene transfer in severe hemophilia A. N\u00a0Engl J Med. 2017;377(26):2519\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1708483.","journal-title":"N Engl J Med"},{"issue":"1","key":"2368_CR72","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi\u00a0KJ, Rangarajan\u00a0S, Mitchell\u00a0N, Lester\u00a0W, Symington\u00a0E, Madan\u00a0B, et\u00a0al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N\u00a0Engl J Med. 2020;382(1):29\u201340.","journal-title":"N Engl J Med"},{"key":"2368_CR73","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti\u00a0G, Gross\u00a0D\u2011A, Mingozzi\u00a0F. Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol. 2020;11:670. https:\/\/doi.org\/10.3389\/fimmu.2020.00670.","journal-title":"Front Immunol"},{"key":"2368_CR74","doi-asserted-by":"publisher","unstructured":"Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J\u00a0Thromb Haemost. 2015;13 Suppl 1:133\u201342. https:\/\/doi.org\/10.1111\/jth.12926.","DOI":"10.1111\/jth.12926"},{"issue":"2","key":"2368_CR75","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"LV Jeune","year":"2013","unstructured":"Jeune\u00a0LV, Joergensen\u00a0JA, Hajjar\u00a0RJ, Weber\u00a0T. Pre-existing anti-adeno-associated virus antibodies as a\u00a0challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24(2):59\u201367. https:\/\/doi.org\/10.1089\/hgtb.2012.243.","journal-title":"Hum Gene Ther Methods"},{"issue":"3","key":"2368_CR76","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz\u00a0M, Levy\u00a0DI, Petropoulos\u00a0CJ, Bashirians\u00a0G, Winburn\u00a0I, Mahn\u00a0M, et\u00a0al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31(3):616\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2023.01.010.","journal-title":"Mol Ther"},{"issue":"2","key":"2368_CR77","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/hgtb.2015.037","volume":"26","author":"A Meliani","year":"2015","unstructured":"Meliani\u00a0A, Leborgne\u00a0C, Triffault\u00a0S, Jeanson-Leh\u00a0L, Veron\u00a0P, Mingozzi\u00a0F. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum Gene Ther Methods. 2015;26(2):45\u201353. https:\/\/doi.org\/10.1089\/hgtb.2015.037.","journal-title":"Hum Gene Ther Methods"},{"issue":"3","key":"2368_CR78","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno\u00a0CS, Pierce\u00a0GF, Arruda\u00a0VR, Glader\u00a0B, Ragni\u00a0M, Rasko\u00a0JJ, et\u00a0al. Successful transduction of liver in hemophilia by AAV factor\u00a0IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342\u20137. https:\/\/doi.org\/10.1038\/nm1358.","journal-title":"Nat Med"},{"key":"2368_CR79","doi-asserted-by":"publisher","unstructured":"Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JEJ, et\u00a0al. CD8+ T\u2011cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419\u201322. https:\/\/doi.org\/10.1038\/nm1549.","DOI":"10.1038\/nm1549"},{"key":"2368_CR80","doi-asserted-by":"publisher","unstructured":"Tuddenham E. Genetherapy for haemophilia B. Haemophilia. 2012;18 Suppl 4:13\u20137. https:\/\/doi.org\/10.1111\/j.1365-2516.2012.02823.x.","DOI":"10.1111\/j.1365-2516.2012.02823.x"},{"issue":"8","key":"2368_CR81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahalangu","year":"2023","unstructured":"Mahalangu\u00a0J, Kaczmarek\u00a0R, von Drygalski\u00a0A, Shapiro\u00a0S, Chou\u00a0SC, Ozelo\u00a0MC, et\u00a0al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. New Engl J Med. 2023;388(8):694\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa2211075.","journal-title":"New Engl J Med"},{"issue":"8","key":"2368_CR82","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe\u00a0SW, Leebeek\u00a0FWG, Recht\u00a0M, Key\u00a0NS, Castaman\u00a0G, Miesbach\u00a0W, et\u00a0al. Gene therapy with etranacogene dezaparvovec for hemophilia B. New Engl J Med. 2023;388(8):706\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2211644.","journal-title":"New Engl J Med"},{"issue":"11","key":"2368_CR83","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/jcm10112471","volume":"10","author":"PE Monahan","year":"2021","unstructured":"Monahan\u00a0PE, N\u00e9grier\u00a0C, Tarantino\u00a0M, Valentino\u00a0LA, Mingozzi\u00a0F. Emerging immunogenicity and genotoxicity considerations of adeno-associated virus vector gene therapy for hemophilia. J\u00a0Clin Med. 2021;10(11):2471. https:\/\/doi.org\/10.3390\/jcm10112471.","journal-title":"J Clin Med"},{"issue":"1","key":"2368_CR84","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","volume":"4","author":"F Mingozzi","year":"2017","unstructured":"Mingozzi\u00a0F, High\u00a0KA. Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape. Annu Rev Virol. 2017;4(1):511\u201334.","journal-title":"Annu Rev Virol"},{"issue":"21","key":"2368_CR85","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani\u00a0AC, Reiss\u00a0UM, Tuddenham\u00a0EG, Rosales\u00a0C, Chowdary\u00a0P, McIntosh\u00a0J, et\u00a0al. Long-term safety and efficacy of factor\u00a0IX gene therapy in hemophilia B. N\u00a0Engl J Med. 2014;371(21):1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa1407309.","journal-title":"N Engl J Med"},{"issue":"23","key":"2368_CR86","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George\u00a0LA, Sullivan\u00a0SK, Giermasz\u00a0A, Rasko\u00a0JEJ, Samelson-Jones\u00a0BJ, Ducore\u00a0J, et\u00a0al. Hemophilia B gene therapy with a\u00a0high-specific-activity factor\u00a0IX variant. N\u00a0Engl J Med. 2017;377(23):2215\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708538.","journal-title":"N Engl J Med"},{"issue":"10","key":"2368_CR87","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","volume":"114","author":"F Mingozzi","year":"2009","unstructured":"Mingozzi\u00a0F, Meulenberg\u00a0JJ, Hui\u00a0DJ, Basner-Tschakarjan\u00a0E, Hasbrouck\u00a0NC, Edmonson\u00a0SA, et\u00a0al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T\u00a0cells. Blood. 2009;114(10):2077\u201386. https:\/\/doi.org\/10.1182\/blood-2008-07-167510.","journal-title":"Blood"},{"issue":"9","key":"2368_CR88","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1182\/blood-2003-10-3591","volume":"103","author":"HZ Miao","year":"2004","unstructured":"Miao\u00a0HZ, Sirachainan\u00a0N, Palmer\u00a0L, Kucab\u00a0P, Cunningham\u00a0MA, Kaufman\u00a0RJ, et\u00a0al. Bioengineering of coagulation factor\u00a0VIII for improved secretion. Blood. 2004;103(9):3412\u20139. https:\/\/doi.org\/10.1182\/blood-2003-10-3591.","journal-title":"Blood"},{"key":"2368_CR89","doi-asserted-by":"publisher","unstructured":"Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA; US Hemophilia Treatment Center Network. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv. 2018;2(16):2136\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2018020552.","DOI":"10.1182\/bloodadvances.2018020552"},{"key":"2368_CR90","doi-asserted-by":"publisher","unstructured":"Liu Q, Fischer U, Wang F, Dreyfuss, G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a\u00a0complex with spliceosomal snRNP proteins. Cell. 1997;90(6):1013\u201321. https:\/\/doi.org\/10.1016\/s0092-8674(00)80367-0.","DOI":"10.1016\/s0092-8674(00)80367-0"},{"key":"2368_CR91","doi-asserted-by":"publisher","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371(9630):2120\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(08)60921-6.","DOI":"10.1016\/S0140-6736(08)60921-6"},{"issue":"4","key":"2368_CR92","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.nurt.2008.08.007","volume":"5","author":"M Oskoui","year":"2008","unstructured":"Oskoui\u00a0M, Kaufmann\u00a0P. Spinal muscular atrophy. Neurotherapeutics. 2008;5(4):499\u2013506. https:\/\/doi.org\/10.1016\/j.nurt.2008.08.007.","journal-title":"Neurotherapeutics"},{"key":"2368_CR93","doi-asserted-by":"publisher","unstructured":"Munsat TL. Workshop report: International SMA collaboration. Neuromuscul Disord. 1991;1(2):81. https:\/\/doi.org\/10.1016\/0960-8966(91)90052-T.","DOI":"10.1016\/0960-8966(91)90052-T"},{"key":"2368_CR94","unstructured":"Summary of Product Characteristics Spinraza\u00ae."},{"issue":"4","key":"2368_CR95","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"HSM Nusinersen","year":"2017","unstructured":"Nusinersen\u00a0HSM. First global approval. Drugs. 2017;77(4):473\u20139. https:\/\/doi.org\/10.1007\/s40265-017-0711-7.","journal-title":"Drugs"},{"key":"2368_CR96","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","volume":"219","author":"VA Sansone","year":"2020","unstructured":"Sansone\u00a0VA, Pirola\u00a0A, Albamonte\u00a0E, Pane\u00a0M, Lizio\u00a0A, D\u2019Amico\u00a0A, et\u00a0al. Respiratory needs in patients with type\u00a01 spinal muscular atrophy treated with nusinersen. J\u00a0Pediatr. 2020;219:223\u2013228.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2019.12.047.","journal-title":"J Pediatr"},{"key":"2368_CR97","unstructured":"Summary of Product Characteristics Evrysdi\u00ae."},{"issue":"7","key":"2368_CR98","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell\u00a0JR, Al-Zaidy\u00a0SA, Lehman\u00a0KJ, McColly\u00a0M, Lowes\u00a0LP, Alfano\u00a0LN, et\u00a0al. Five-year extension results of the phase\u00a01 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78(7):834\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2368_CR99","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss\u00a0KA, Farrar\u00a0MA, Muntoni\u00a0F, Saito\u00a0K, Mendell\u00a0JR, Servais\u00a0L, et\u00a0al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase\u00a0III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01867-3.","journal-title":"Nat Med"},{"key":"2368_CR100","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-zolgensma-onasemnogene-abeparvovec-fatal-cases_en.pdf.."},{"issue":"7","key":"2368_CR101","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne\u00a0M, Tattoli\u00a0I, Delestree\u00a0N, Recinos\u00a0Y, Workman\u00a0E, Shihabuddin\u00a0LS, et\u00a0al. Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci. 2021;24(7):930\u201340. https:\/\/doi.org\/10.1038\/s41593-021-00827-3.","journal-title":"Nat Neurosci"},{"key":"2368_CR102","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","volume":"8","author":"P Colella","year":"2017","unstructured":"Colella\u00a0P, Ronzitti\u00a0G, Mingozzi\u00a0F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2017;8:87\u2013104. https:\/\/doi.org\/10.1016\/j.omtm.2017.11.007.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6289","key":"2368_CR103","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.aaf4770","volume":"352","author":"SH Orkin","year":"2016","unstructured":"Orkin\u00a0SH, Reilly\u00a0P. Paying for future success in gene therapy. Science. 2016;352(6289):1059\u201361. https:\/\/doi.org\/10.1126\/science.aaf4770.","journal-title":"Science"},{"issue":"1","key":"2368_CR104","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/hae.14907","volume":"30","author":"C Ay","year":"2024","unstructured":"Ay\u00a0C, Frenzel\u00a0L, Pinachyan\u00a0K, Le Quellec\u00a0S. Gene therapy for haemophilia A and\u00a0B, from basic principles to clinical implementation: An illustrated review. Haemophilia. 2024;30(1):5\u201315. https:\/\/doi.org\/10.1111\/hae.14907.","journal-title":"Haemophilia"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02368-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-024-02368-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-024-02368-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T05:55:35Z","timestamp":1747288535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-024-02368-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":104,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2368"],"URL":"https:\/\/doi.org\/10.1007\/s00508-024-02368-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Ay received honoraria for lectures and\/or participation in advisory boards from CSL Behring, Sobi, LFP, Roche, Biotest, BioMarin, Bayer and Pfizer. A.\u00a0Reinisch received honoraria for lectures and\/or participation in advisory boards from CSL Behring, BioMarin, Pfizer, Novo Nordisk and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}